Successful use of ketamine to treat severe depression with suicidality post-COVID-19 - A case report
Related Experiment Video
Updated: Aug 15, 2025

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats
Published on: May 22, 2019
Sharma Meha1, Satish Suhas1, Naren P Rao1
1Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, India.
Abstract:
Every second patient who suffers from COVID-19 experiences is at risk for depression. The treatment of severe depression with suicidal risk is challenging in patients with COVID-19 given the restrictions in access to and safety concerns with the use of electroconvulsive therapy during the COVID pandemic. Although ketamine is effective in treating depression, especially in presence of acute suicidality, to date, there are no reports on ketamine use to treat severe depression in the context of COVID-19. In this case report, we describe the success of ketamine to treat a person with severe depression and suicidality following COVID-19 infection.
More Related Videos
Related Concept Videos
Electroconvulsive Therapy
Psychosis: Goals of Pharmacotherapy
Antidepressant Drugs: MAOIs and Other Agents
Drug Therapy
Antianxiety Medications
Depression: Overview
Long-term Depression

